Unit 10 Assignment

Communicating Results of Drug Diversion and Prevention Program at MWHC Jacques A. Bateko Capella University PSY5140: Program Evaluation Instructor: Dr. Bill Huitt Spring 2023

What is the Drug Diversion and Prevention at MWHC?  Protection of Patients and associates from Drug diversion  Support and enhance MWHC’s commitment to HRO  Raise awareness of controlled substances  Enhance accountability in detecting, preventing, and responding to drug diversion and prescription fraud

Introduction  Program Background  Program Goals and Objectives  Program methods and strategies

Program Methods & Strategies Inputs What do they invest  Staff  Volunteers  Time  Finance  Technology  Equipment  Facilities/ training  Research findings  Material  Partners  Sponsors (donors). Activities What they do  Associate training  Diversion prevention  Diversion detection  Diversion Response  DEA Accountability Investigation  Enhance Knowledge of regulatory and Medstar Health requirements  Raise awareness of controlled substances Who they Reach  Medstar Health care Recipients  Clients  Participants  Clinicians  Associates  Professional  Community-based organization  Local Government Agencies  Federal Government Agencies Short term Goals  Establish a controlled substance regulatory training  Describe the DEA audit accountability  Increase program efficacy  Improve community safety  Decrease prescription fraud  Raise awareness of controlled substances Long term Goals  End drug diversion and prescription fraud  Drug Diversion eradication  Establish workplace safety

Cost-Benefit Analysis Cost-Benefit Analysis  Safe work environment  Prevention of legal problems  Enhance knowledge of controlled substances  Prevention of diversion and fraud  Establishment of systemwide drug diversion protocol  Community safety and wellness Cost-Benefit Analysis

Evaluation Methods Data Collection & Analysis Overview: Data Collection & Analysis  Interviews  Surveys self-Report  Focus groups  Direct Observation  Records from previous Evaluations  Secondary sources

Implementation Plan Strategies  Objectives-based Approach  Quasi-experimental approach: interrupted time series analysis Strategies

Ethical considerations Ethical consideration  Protection from harm  Dignity and respect  Prevent Conflict of interest  Competence  Systematic inquiry  Integrity  Protection of data

Recommendation  Creating a holistic approach (engaging all functions and all levels of the organization)  Using a holistic tech-aid strategy  Elaborate clear policies  Increase staff in the executive committee of the program  Consequent financial support  Creating a family-based education subprogram

Conclusion  The drug diversion prevention team (DDPT) at MedStar health system is an important program that promotes community safety and wellness.  The evaluation of this program allows participants and stakeholders to continue to improve and reinforce the program  Different methods and strategies had helped to investigate the effectiveness and functionality of the program

References  American Psychological Association. (2017). Ethical principles of psychologists and code of conduct. http://www.apa.org/ethics/code/index.aspx  Berge, K. H., Dillon, K. R., Sikkink, K. M., Taylor, T. K., & Lanier, W. L. (2012). Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention.  Mayo Clinic Proceedings ,  87 (7), 674–682. https://doi.org/10.1016/j.mayocp.2012.03.013  MedStar Washington Hospital Center" .  US News . Retrieved May 07, 2023.

References  Royse, D., Thyer, B. A., & Padgett, D. K. (2015). Program Evaluation: An Introduction to an Evidence- Based Approach (6th Edition). Cengage Limited. https://capella.vitalsource.com/books/9781285227931  Siegel, J., & O'neal, B. (2007). Code N: a multidisciplinary approach to proactive drug diversion prevention.  Hospital Pharmacy ,  42 (3), 244-248.  Crowley, D. M., Jones, D. E., Coffman, D. L., & Greenberg, M. T. (2014). Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost-effectiveness of universal prevention in the PROSPER trial.  Preventive Medicine ,  62 , 71-77.  Kontopantelis, E., Doran, T., Springate, D. A., Buchan, I., & Reeves, D. (2015). Regression-based quasi-experimental approach when randomization is not an option: interrupted time series analysis.  BMJ ,  350 .